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Abstract Recent studies have described a number of genes
that are frequently altered in medulloblastoma tumors and
that have putative key roles in the development of the dis-
ease. We hypothesized that common germline genetic vari-
ations in these genes may be associated with
medulloblastoma development. Based on recent publica-
tions, we selected 10 genes that were frequently altered in
medulloblastoma: CCND2, CTNNB1, DDX3X, GLI2,
SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 (now
renamed as KMT2D). Common genetic variants (single
nucleotide polymorphisms) annotating these genes
(n = 221) were genotyped in germline DNA (neonatal dried
blood spot samples) from 243 childhood medulloblastoma
cases and 247 control subjects from Sweden and Denmark.
Eight genetic variants annotating three genes in the sonic
hedgehog signaling pathway; CCND2, PTCH1, and GLI2,
were found to be associatedwith the risk ofmedulloblastoma
(Pcombined\ 0.05). The findings were however not statisti-
cally significant following correction for multiple testing by
the very stringent Bonferroni method. The results do not
support our hypothesis that common germline genetic vari-
ants in the ten studied genes are associated with the risk of
developing medulloblastoma.
Keywords Medulloblastoma  PNET  Primitive
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Genetic variation
Introduction
Medulloblastoma is a rare, embryonal tumor of the cere-
bellum that occurs predominantly in children [1]. Intensive
treatment, including surgery, chemotherapy, and radio-
therapy, cures about two-thirds of all children that are
diagnosed with the disease [1, 2]. However, the children
who survive often suffer from serious and disabling late
side effects, such as neurocognitive dysfunction and risk of
secondary malignancies.
A small subset of medulloblastomas is seen in individ-
uals with predisposing genetic syndromes, caused by
germline mutations in PTCH1 or SUFU (Gorlin syn-
drome), APC (Turcot syndrome), and TP53 (Li Fraumeni
syndrome) [3, 4]. Because the tumor occurs early in life,
even in very young children and infants, and because there
are no established environmental risk factors for medul-
loblastoma [2], the presence of additional genetic factors
that increase the risk of this disease is plausible.
Recent studies have reported a number of genes in which
somatic mutations and copy number alterations have been
detected in multiple medulloblastoma tumors. Among
the most frequently altered genes are well known oncogenes
and tumor suppressors (e.g., MYC, TP53, and PTCH1)
as well as novel medulloblastoma candidate genes
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(e.g.,MML2) [5–10]. The aim of this study was to investigate
if common germline genetic variations [single nucleotide
polymorphisms (SNPs)] are associated with increased risk of
developing medulloblastoma in children and young adults.
For this purpose, we applied a target gene approach, focusing




In Sweden, 136 medulloblastoma cases born between 1975
and 2002, diagnosed before the age of 25, and present in the
Swedish phenylketonuria screening registry were included
in the study. Equally many control subjects, matched to each
case by year of birth, were drawn from the same biobank.
For five cases, matching by year of birth was not possible,
and controls were matched by year of birth ± 5 years.
Matching by gender was not possible due to an overrepre-
sentation of females among consenting individuals. Nine
Swedish case and eight Swedish control samples were
removed due to technical issues. In Denmark, 128 medul-
loblastoma cases born between 1982 and 2008, diagnosed
before the age of 20, and present in the Danish Newborn
Screening Biobank were included in the study. Equally
many control subjects, matched to each case by year of birth
and gender, were drawn from the same biobank. One Danish
case was removed due to technical issues.
DNA extraction and genotyping
DNA was extracted from dried blood spot samples (DBSS)
collected from each subject close to birth, and stored at the
Swedish phenylketonuria screening registry and the Danish
Newborn Screening Biobank. Two disks were punched
from each participant’s DBSS. DNA was extracted using
the Extract-N-amp kit (Sigma-Aldrich) as described pre-
viously [11–13]. The extracted DNA was whole-genome-
amplified using the REPLIg kit (QIAGEN; Danish sam-
ples) or the GenomePlex single cell whole genome
amplification (WGA) kit (Sigma-Aldrich; Swedish sam-
ples) according to the manufactures’ instructions. Both kits
have been shown to perform well in the downstream
analyses used in this study [11]. Genotyping was per-
formed using HumanOmni2.5-8 BeadChips (Illumina) at
Aros, Denmark. WGA specific cluster files were generated
and genotypes called using GenomeStudio V2010.3 (Illu-
mina) and GenomeStudio Genotyping Analysis Module
1.8.4. Four subjects (one Swedish case, one Danish case,
and two Danish controls) had a call-rate\97 % and were
excluded from further analyses, whereas all other samples
had a call-rate[97 %, indicating good DNA quality. SNPs
were excluded based on the following criteria in either data
set: call-rate\95 %, minor allele frequency\1 %, Hardy–
Weinberg test P\ 1 9 10-6, and missing genotypes non-
randomly distributed between cases and controls.
Selection of candidate genes and SNPs
Ten genes (CCND2, CTNNB1, DDX3X, GLI2, SMARCA4,
MYC, MYCN, PTCH1, TP53 and MLL2, Supplementary
Table 1) were selected for investigation because they were
known to have a well-defined biological function and were
among the most commonly altered genes in medulloblas-
toma tumors [5–10]. Two hundred and twenty-one SNPs
annotating these genes fulfilled the criteria for inclusion in
both datasets (Supplementary Tables 1, 2).
Statistical analyses
Odds ratios (ORs) and 95 % confidence intervals (95 %
CIs) were calculated for the Swedish and Danish datasets
separately using unconditional logistic regression. ORs and
P values for the combined dataset were then estimated
using a fixed-effect model meta-analysis. To account for
multiple testing, Bonferroni correction was performed.
Statistical calculations and data management were done
using PLINK (version 1.07, http://pngu.mgh.harvard.edu/
purcell/plink/) [14]. We used principal component analysis
(EIGENSOFT [15, 16]) to identify and exclude five
Swedish (three cases and two controls) and 11 Danish (six
cases and five controls) outlier individuals.
Results
In the final analyses, 123 medulloblastoma cases and 126
control subjects from Sweden and 120 medulloblastoma cases
and 121 control subjects from Denmark were included
(Table 1). Risk estimates for 221 investigated genetic variants
(annotated to CCND2, CTNNB1, DDX3X, GLI2, SMARCA4,
MYC,MYCN, PTCH1, TP53, andMLL2) are listed in Supple-
mentary Table 2. Eight variants annotating CCND2, PTCH1,
andGLI2were associatedwith risk ofmedulloblastoma (for all
eight variants, Pcombined\0.05; Table 2, Supplementary
Table 3). These findings were however not statistically sig-
nificant after Bonferroni correction for multiple comparisons.
Discussion
The identification of common germline genetic variation
that predispose to medulloblastoma development could
increase our understanding of the disease and may
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facilitate the development of targeted therapeutics and
measures of prevention. In our study, eight genetic vari-
ants, annotating three genes involved in the sonic
hedgehog signaling pathway (CCND2, PTCH1, and
GLI2), were indicted as associated with medulloblastoma
risk. The associations were however not statistically sig-
nificant following Bonferroni correction for multiple
comparisons, which on the other hand may be overly
conservative as many of the variants are in linkage dis-
equilibrium with each other.
Recent studies of the somatic landscape of medul-
loblastoma tumors have described recurrent alterations,
including mutations and copy number aberrations, in the
ten genes selected for investigation in the present study [5–
10]. Previous knowledge of gene function also contributes
to the plausible roles of the selected genes in medul-
loblastoma tumourigenesis. Rare germline mutations in
PTCH1 are known to cause Gorlin syndrome (also called
basal cell naevus syndrome) giving carriers a sensitivity to
ionizing radiation and an increased risk of jaw cysts, basal
cell carcinoma and about 5 % life time risk for developing
medulloblastoma [17]. GLI family zinc finger 2 (GLI2)
encodes a transcription factor that mediates SHH signaling
at the distal end of the pathway and CCND2 is coding for
the cyclin D2 protein, which is a central regulator of cell
cycling.
A strength of this study was that all included cases were
medulloblastoma, whereas many previous studies have
analyzed medulloblastoma combined with other childhood
brain tumors [18–20]. However, medulloblastoma is a
heterogeneous disease which can be divided into different
subgroups based on tumor histology (histological sub-
groups) or patterns of gene expression in the tumor
(molecular subgroups) [21]. If a genetic variant is associ-
ated with only one of the medulloblastoma subgroups, the
result for this variant would be diluted when analyzing all
medulloblastoma together, possibly generating a false
negative result. We could not stratify the included subjects
by histological or molecular subtypes of their tumors due to
the limited size of the study and the fact that we did not
have access to a full pathology review or tumor tissue for
all cases.
This is one of the first population based studies of
potential etiologic common germline genetic variants in
medulloblastoma. Increased understanding of genetic
variation in genes important in medulloblastoma tumouri-
genesis could feed into clinical and health science per-
spectives of intervention and protection against gene-
environment interactions. Because medulloblastoma is a
rare disease, an international consortium is necessary to
increase the number of samples and get statistical power
sufficient for genome-wide analyses and in depth interro-
gation of candidate genes that contribute to medulloblas-
toma etiology.
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Table 1 Study subjects
Swedish cases Swedish controls Danish cases Danish controls
Total (n) 123 126 120 121
Sex
Male (n) 77 61 68 67
Female (n) 46 65 52 54
Table 2 Genetic variations in
GLI2, PTCH1 and CCND2 and
association with
medulloblastoma risk
SNP [minor/major (ref) allele]a Gene ORcombined (95 % CI)
b Pcombined
b
rs13008945 (G/A) GLI2 0.70 (0.50–0.97) 0.033
rs2121992 (A/G) GLI2 0.72 (0.52–0.99) 0.046
rs4848628 (C/A) GLI2 0.68 (0.48–0.98) 0.039
rs11122821 (G/A) GLI2 0.74 (0.57–0.95) 0.018
rs1992900 (A/G) GLI2 1.32 (1.00–1.75) 0.049
rs77224875 (G/A) PTCH1 0.45 (0.25–0.81) 0.008
rs3217805 (G/C) CCND2 0.67 (0.51–0.87) 0.003
rs4372527 (G/A) CCND2 1.38 (1.04–1.82) 0.024
a Only SNPs with Pcombined\ 0.05 are listed in this table. ORs and P values for all investigated SNPs are
found in Supplementary Table 2
b Risk estimates were calculated in the Swedish and the Danish datasets separately (Supplementary
Table 3), and then combined using fixed-effect model meta-analysis
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